Aim: To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection.
Methods: A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival.
Results: PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group: (1) the recurrence-free rate increased from 50% to 63%, and (2) time to recurrence at the 36th percentile was postponed by 78%. The efficacy of administering PI-88 at 250 mg/d was confounded by a high dropout rate (11 out of 54 patients). Additionally, subgroup analyses of patients with (1) multiple tumors or a single tumor ≥ 2 cm; and (2) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage (56.8% improvement in disease-free survival, P = 0.045) for patients with both risk factors for recurrence.
Conclusion: Administering PI-88 at 160 mg/d is a safe and well-tolerated dosage that may confer significant clinical benefits for patients with HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145780 | PMC |
| http://dx.doi.org/10.3748/wjg.v20.i32.11384 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.
Diabetol Metab Syndr
December 2024
Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Road, Shanghai, 200127, China.
Aims: To observe the effects of liraglutide on abdominal fat distribution in Chinese subjects with obesity in 12 weeks, and further to explore the correlation between abdominal fat content and glucose metabolism after monotherapy.
Methods: This study recruited 71 obese subjects. All the subjects have received liraglutide monotherapy (0.
The treatment of gout includes anti-inflammatory therapy and prophylaxis of flare-ups on the one hand and measures for long-term uric acid reduction on the other. Acute arthritis urica is best relieved by intra-articular steroids; systemic steroids, NSAIDs and, in exceptional cases, colchicine are also suitable. For the prophylaxis of relapses, long-term use of colchicine, NSAIDs or low-dose steroids is an option.
View Article and Find Full Text PDFPregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa: A Randomized Crossover Trial.
JAMA Dermatol
December 2024
Division of Dermatology, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Article Synopsis
- Patients with recessive dystrophic epidermolysis bullosa (RDEB) often suffer from neuropathic pain and itch, but there is limited evidence on effective treatments for these symptoms.
- A randomized, double-blinded crossover trial was conducted to evaluate the efficacy of pregabalin (50-300 mg/d) compared to a placebo in treating these symptoms in RDEB patients aged 8 to 40.
- The study included 10 participants who received both treatments in a randomized order, and the main outcome measured was the difference in pain and itch scores using a visual analog scale before and after the interventions.
Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.
J Am Coll Cardiol
October 2024
Department of Medicine, University of Mississippi, Jackson, Mississippi, USA.
Article Synopsis
- Hyperkalemia (HK) impacts the effectiveness of renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists (MRAs) in patients with heart failure with reduced ejection fraction (HFrEF).
- The study analyzed patients with HFrEF and either HK or a history of HK during a run-in phase designed to optimize their RAS inhibitor and MRA doses using patiromer.
- Results showed significant increases in the use of RAS inhibitors and MRAs among patients meeting the optimization criteria, indicating that patiromer helped enhance treatment for those with HK or a history of HK.
Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.
JAMA Dermatol
November 2024
Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
Article Synopsis
- China faces a significant challenge with postherpetic neuralgia, necessitating effective new treatment options that minimize neurotoxic effects compared to current calcium channel ligands.
- The study aimed to evaluate the efficacy and safety of crisugabalin, a new oral medication, involving a randomized clinical trial across 48 care centers in China, which included a 12-week treatment phase and a subsequent 14-week extension phase.
- Results showed improvement in pain relief for patients taking crisugabalin, particularly at the 40 mg and 80 mg doses, highlighting its potential as a more effective treatment for managing postherpetic neuralgia compared to a placebo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!